stock-detail (PPHM)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Walgreens Shuts 40 Theranos Outlets After Ending Partnership

6/13/2016 12:02 pm

(Bloomberg) June 12, 2016 - Walgreens Boots Alliance Inc. said it has terminated its relationship with blood-testing startup Theranos Inc. and will close the company’s testing centers in its stores.

Pathologists Often Disagree on Biopsy Findings

3/30/2016 11:04 am

(Medscape Medical News) Mar 30, 2016 - Pathologists largely agree with each other when identifying invasive breast cancer on breast biopsy slides, but agreement is much lower when those slides suggest atypia or ductal carcinoma in situ (DCIS), according to a recent study.

U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast Cancer

2/5/2016 12:00 pm

(NASDAQ) Feb 5, 2016 - Immunomedics, Inc., today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease.

OSE Pharma Announces U.S. Initiation of Atalante 1, the Company's Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer

2/5/2016 11:03 am

(Yahoo! Finance) Feb 4, 2016 - OSE Pharma SA, an immuno-oncology company developing a T-specific immunotherapy for late-stage cancer patients, today announced initiation in the United States of its Phase 3 clinical trial, Atalante 1. This global, pivotal trial will evaluate Tedopi®, the company's lead product, for advanced non-small cell lung cancer (NSCLC).

NIH Researchers Identify Striking Genomic Signature Shared By Five Types Of Cancer

2/5/2016 11:02 am

(NIH) Feb 5, 2015 - National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer.

What Race Has to Do With Breast Cancer

10/13/2015 11:04 am

(TIME) Oct 12, 2015 - Researchers provide the most detailed look yet at why minority women tend to fare worse with breast cancer.

Rare Childhood Leukemia Reveals Surprising Genetic Secrets

10/13/2015 11:04 am

(UCSF) Oct 12, 2015 - A coalition of leukemia researchers led by scientists from UC San Francisco has discovered surprising genetic diversity in juvenile myelomonocytic leukemia (JMML), a rare but aggressive childhood blood cancer.

Is This Cancer Treatment Worth It? New Tool Offers Patients Data

10/13/2015 11:03 am

(Bloomberg) Oct 13, 2015 - For the first time, a consortium of top U.S. cancer hospitals will provide patients with guidance about the cost of drugs used in their treatment, helping address a concern for many people undergoing a major medical event -- what the financial repercussions of their condition are.

Exclusive - Transatlantic Divide: How U.S. Pays Three Times More For Drugs

10/12/2015 12:02 pm

(Reuters) Oct 12, 2015 - U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.

Rosetta Genomics Launches BRAF Mutation Assay

10/12/2015 11:05 am

(MarketWatch) Oct 12, 2015 - Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. This newest assay will complement its broad offerings so that oncologists can optimize treatment decisions for their cancer patients.

Roche Wins the First HPV Primary Screening Tender in Europe

10/12/2015 11:05 am

(Roche) Oct 12, 2015 - Roche announced today that it has been awarded a 5-year contract by the National Institute for Public Health and the Environment (RIVM) in the Netherlands for implementation of the cobas® HPV Test as the first-line, primary screening test in the national cervical cancer screening program.

Stand Up To Cancer Makes $7.5 Million in Cancer Research Funding Available to Early-career Scientists

10/12/2015 11:05 am

(AACR) Oct 9, 2015 - Stand Up To Cancer (SU2C) is making $7.5 million in research funding available to early-career scientists who are pursuing innovative approaches to cancer, the American Association for Cancer Research (AACR) announced today. A total of 10 Innovative Research Grants (IRGs) will be funded up to $750,000 each over three years.

UK Charity Unveils £100M Cancer Grants Scheme

10/12/2015 11:05 am

(PharmaTimes [UK]) Oct 12, 2015 - Cancer Research UK has this morning launched its mammoth Grand Challenges cancer grants scheme, which will offer up an overall investment of £100 million to help overcome the greatest barriers to beating the disease.

Novartis to Invest Further $15M in Gamida Cell

10/12/2015 11:04 am

(Globes [Israel]) Oct 10, 2015 - Multinational pharmaceutical giant Novartis International AG has announced that it is investing up to an additional $15 million in Israeli stem cell company Gamida Cell.

To Die At Home, It Helps To Have Someone Who Can Take Time Off Work

10/12/2015 11:04 am

(NPR/Shots blog) Oct 9, 2015 - A wide base of support is needed in order for a patient's wish to die at home to be made real — including, in some cases, whether someone can take time off work to be with their loved one in their final days, a study finds.

Bigger Challenges For Rural Cancer Patients

10/12/2015 11:04 am

(The Gazette [Cedar Rapids, IA]) Oct 11, 2015 - Rural Americans fighting cancer face even more challenges than those who live in more urban areas, including a lack of nearby physicians and treatment, transportation issues, and access to cancer screenings and follow-up care.

Eli Lilly's Good Cholesterol Drug Went Bad. Here's What That Means For Pharma

10/12/2015 11:03 am

(Forbes) Oct 12, 2015 - This morning, Eli Lilly announced that evacetrapib, its experimental drug to raise good cholesterol, failed to prevent patients from getting heart attacks and strokes in a large clinical trial.

Value-Based Payments: But Is There Any Value for Doctors?

10/12/2015 11:03 am

(Medscape Business of Medicine) Oct 8, 2015 - The health system is moving toward value-based medicine, a care-management strategy that pays doctors for pursuing high quality while simultaneously reducing costs.

Merck KGaA Bets On Cancer Drugs To Revitalize German Firm

10/12/2015 11:03 am

(Reuters) Oct 12, 2015 - Merck KGaA is betting on its oncology pipeline to revitalize the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif.

FDA Expands Use of Nivolumab in Lung Cancer

10/12/2015 11:01 am

(Medscape Medical News) Oct 9, 2015 - The US Food and Drug Administration (FDA) today expanded the approved use of nivolumab (Opdivo, Bristol-Myers Squibb) to include the treatment of patients with metastatic nonsquamous, non-small-cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy.

Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform

7/8/2015 11:04 am

(MarketWatch) July 8, 2015 - Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 inhibitor, and Opdivo® (nivolumab), a PD-1 inhibitor.

GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin

5/13/2015 11:05 am

(GenSpera) May 13, 2015 - GenSpera, Inc. announced today the successful completion of the first stage of an ongoing Phase II study of its lead investigational agent, mipsagargin (G-202), in glioblastoma (brain cancer) and the continuation of enrollment for an expansion phase of the trial.

Medica and Minnesota Oncology Collaborate to Improve Patient Support Services

3/26/2015 12:03 pm

(The US Oncology Network) Mar 26, 2015 - Minnesota Oncology, the premier cancer physician group throughout the Twin Cities and an affiliate of The US Oncology Network, today announced that as of January 1, 2015, select Medica members have access to a comprehensive cancer care management program.

World's Most Popular Weed-killer Labeled 'Probable Carcinogen'

3/23/2015 12:00 pm

(Chicago Tribune/Associated Press) Mar 23, 2015 - One of the world's most popular weed-killers — and the most widely used kind in the U.S. — has been labeled a probable carcinogen by the International Agency for Research on Cancer.

ERYTECH Reports Additional Positive Phase III Results From Clinical Study With ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia

12/8/2014 05:01 pm

(CNBC) Dec 8, 1014 - ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia.